Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10340277 | 0.82 | ALDH1A1 (0.42) | MAPTLMNATSHRHTTMEN1 | |
| SCHEMBL24127319 | 0.76 | CA12 (0.41) | LMNATSHRTP53EGFRERBB2 | |
| SCHEMBL6509218 | 0.75 | — | — | |
| SCHEMBL11150573 | 0.74 | — | — | |
| SCHEMBL8149191 | 0.74 | HSD17B10 (0.35) | LMNAEGFRERBB2HSD17B10TDP1 | |
| SCHEMBL571432 | 0.73 | TSHR (0.35) | MAPTLMNATSHRHTTTP53 | |
| SCHEMBL995987 | 0.73 | TSHR (0.37) | MAPTLMNATSHRHTTTP53 | |
| SCHEMBL8940796 | 0.73 | MAPT (0.40) | MAPTLMNAHSD17B10TDP1ALDH1A1 | |
| SCHEMBL483128 | 0.73 | CA12 (0.55) | TSHRTP53EGFRERBB2MEN1 | |
| SCHEMBL474902 | 0.73 | MAPT (0.40) | MAPTLMNAHSD17B10TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103224476-A | New process for preparing 1-[2-(2-hydroxyethoxy)ethyl]piperazine through diethanolamine method | SHANGGAO RUIYA FINE CHEMICALS CO LTD | 2013-07-31 | — | — | CN | disclosed |
| US-7635464-B2 | Selective targeting of apoptotic cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-22 | — | — | US | disclosed |
| US-7635464-B2 | Selective targeting of apoptotic cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-22 | — | — | US | disclosed |
| US-20090311179-A1 | Selective Targeting of Apoptotic Cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-17 | — | — | US | disclosed |
| US-20090311179-A1 | Selective Targeting of Apoptotic Cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-17 | — | — | US | disclosed |
| US-6281365-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-08-28 | — | — | US | disclosed |
| EP-0232784-B1 | (GEM-HETEROCYCLODIMETHANAMINE-N,N')PLATINUM COMPLEXES | AMERICAN CYANAMID COMPANY (US) | 1992-12-02 | — | — | EP | disclosed |
| US-4880790-A | ANTICANCER, ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0232784-A2 | (Gem-heterocyclodimethanamine-N,N')platinum complexes | AMERICAN CYANAMID COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0060610-B1 | HEXAHYDRO-TRANS- AND TETRAHYDROPYRIDOINDOLE NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
| US-4432978-A | NEUROLEPTIC AGENTS, TRANQUILIZERS | PFIZER INC. (US) | 1984-02-21 | — | — | US | disclosed |
| US-4431649-A | TRANQUILIZERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4431646-A | TRANQUILIZERS; PSYCHOSIS; NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4427679-A | TRANQUILIZERS; PSYCHOLOGICAL DISORDERS | PFIZER INC. (US) | 1984-01-24 | — | — | US | disclosed |
| EP-0060610-A1 | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents | PFIZER INC. (US) | 1982-09-22 | — | — | EP | disclosed |
| US-4337250-A | NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311179-A1 | Selective Targeting of Apoptotic Cells | BAX, BAD, BCL2 | MAPT 3602/4885LMNA 818/4885TSHR 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.